Joint Formulary & PAD

Cinacalcet hydrochloride - Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis]

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Associated Icons :
NICE
R
SPC
Restrictions / Comments :
Important

Not on Surrey Heartlands Trust formularies. Trusts with renal centres (locally this is Epsom, Frimley & Brighton) will retain prescribing responsibility’.

Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Cinacalcet hydrochloride
Indication :
Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis]
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Cinacalcet hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis] .

  • No records returned.